Autoimmune disorder of the nervous system

This trial tests a therapy called CTX112 in adults with severe neurologic autoimmune diseases, including progressive multiple sclerosis, neuromyelitis optica, and stiff-person syndrome. CTX112 uses donor T cells edited with CRISPR to target and deplete B cells, which are thought …

This trial is testing an experimental therapy called CTA313, which uses engineered immune cells (CAR T cells) to potentially reset the immune system in people with active autoimmune diseases. The study will include adults aged 18 to 75 with systemic lupus erythematosus, progressi…

This study tests whether a low dose of blinatumomab, a drug originally used for leukemia, can help people with severe autoimmune encephalitis or cerebellitis that hasn't responded to standard treatments. The drug targets and depletes certain immune cells (B cells) that are mistak…

This early-stage trial is testing a new treatment called C-CAR168, which uses a patient's own immune cells modified to attack harmful cells in the body. It is for 15 adults with multiple sclerosis, neuromyelitis optica, autoimmune encephalitis, or stiff person syndrome that have …

This early-stage study tests a new cell therapy called HY001N in 15 adults with relapsed or treatment-resistant autoimmune neurological diseases like neuromyelitis optica. The main goal is to check safety and side effects, while also looking for signs of improvement in disability…

Researchers at King's College London are studying how the immune system relates to neuropsychiatric symptoms, which include mental and neurological issues. They will compare blood and spinal fluid samples from people with such symptoms against samples from healthy controls. The g…

This study will follow 1,550 adults with various neurological autoimmune diseases—like multiple sclerosis, myasthenia gravis, and autoimmune encephalitis—to see how these conditions progress and respond to treatments in everyday medical practice. Researchers will measure disabili…